Report Detail

Request for Sample of this report

Pharma & Healthcare Global Tofacitinib Citrate Extended-Release Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032

  • RnM4749396
    • |
  • 05 October, 2026
    • |
  • Global
    • |
  • 92 Pages
    • |
  • GIR
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Tofacitinib Citrate Extended-Release Tablets market size was valued at US$ million in 2025 and is forecast to a readjusted size of US$ million by 2032 with a CAGR of %during review period.
Tofacitinib citrate extended-release tablets refer to a specific pharmaceutical formulation of tofacitinib citrate,a Janus kinase(JAK)inhibitor used in the treatment of certain autoimmune diseases such as rheumatoid arthritis.
This report is a detailed and comprehensive analysis for global Tofacitinib Citrate Extended-Release Tablets market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
Key Features:
Global Tofacitinib Citrate Extended-Release Tablets market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Tofacitinib Citrate Extended-Release Tablets market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Tofacitinib Citrate Extended-Release Tablets market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2021-2032
Global Tofacitinib Citrate Extended-Release Tablets market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2021-2026
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Tofacitinib Citrate Extended-Release Tablets
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Tofacitinib Citrate Extended-Release Tablets market based on the following parameters - company overview, sales quantity, revenue, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Pfizer, Zydus, Sino Therapeutics, Qilu Pharmaceutical, CSPC Ouyi Pharmaceutical, Yichang Humanwell Pharmaceutical, Sichuan Kelun Pharmaceutical, Lepu Pharmaceutical, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
Market Segmentation
Tofacitinib Citrate Extended-Release Tablets market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
11mg per Tablet
22mg per Tablet
Market segment by Application
Rheumatoid Arthritis
Psoriatic Arthritis
Ankylosing Spondylitis
Ulcerative Colitis
Other
Major players covered
Pfizer
Zydus
Sino Therapeutics
Qilu Pharmaceutical
CSPC Ouyi Pharmaceutical
Yichang Humanwell Pharmaceutical
Sichuan Kelun Pharmaceutical
Lepu Pharmaceutical
Market segment by region, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Tofacitinib Citrate Extended-Release Tablets product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Tofacitinib Citrate Extended-Release Tablets, with price, sales quantity, revenue, and global market share of Tofacitinib Citrate Extended-Release Tablets from 2021 to 2026.
Chapter 3, the Tofacitinib Citrate Extended-Release Tablets competitive situation, sales quantity, revenue, and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Tofacitinib Citrate Extended-Release Tablets breakdown data are shown at the regional level, to show the sales quantity, consumption value, and growth by regions, from 2021 to 2032.
Chapter 5 and 6, to segment the sales by Type and by Application, with sales market share and growth rate by Type, by Application, from 2021 to 2032.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value, and market share for key countries in the world, from 2021 to 2026.and Tofacitinib Citrate Extended-Release Tablets market forecast, by regions, by Type, and by Application, with sales and revenue, from 2027 to 2032.
Chapter 12, market dynamics, drivers, restraints, trends, and Porters Five Forces analysis.
Chapter 13, the key raw materials and key suppliers, and industry chain of Tofacitinib Citrate Extended-Release Tablets.
Chapter 14 and 15, to describe Tofacitinib Citrate Extended-Release Tablets sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Tofacitinib Citrate Extended-Release Tablets Consumption Value by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 11mg per Tablet
    • 1.3.3 22mg per Tablet
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Tofacitinib Citrate Extended-Release Tablets Consumption Value by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Rheumatoid Arthritis
    • 1.4.3 Psoriatic Arthritis
    • 1.4.4 Ankylosing Spondylitis
    • 1.4.5 Ulcerative Colitis
    • 1.4.6 Other
  • 1.5 Global Tofacitinib Citrate Extended-Release Tablets Market Size & Forecast
    • 1.5.1 Global Tofacitinib Citrate Extended-Release Tablets Consumption Value (2021 & 2025 & 2032)
    • 1.5.2 Global Tofacitinib Citrate Extended-Release Tablets Sales Quantity (2021-2032)
    • 1.5.3 Global Tofacitinib Citrate Extended-Release Tablets Average Price (2021-2032)

2 Manufacturers Profiles

  • 2.1 Pfizer
    • 2.1.1 Pfizer Details
    • 2.1.2 Pfizer Major Business
    • 2.1.3 Pfizer Tofacitinib Citrate Extended-Release Tablets Product and Services
    • 2.1.4 Pfizer Tofacitinib Citrate Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Pfizer Recent Developments/Updates
  • 2.2 Zydus
    • 2.2.1 Zydus Details
    • 2.2.2 Zydus Major Business
    • 2.2.3 Zydus Tofacitinib Citrate Extended-Release Tablets Product and Services
    • 2.2.4 Zydus Tofacitinib Citrate Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Zydus Recent Developments/Updates
  • 2.3 Sino Therapeutics
    • 2.3.1 Sino Therapeutics Details
    • 2.3.2 Sino Therapeutics Major Business
    • 2.3.3 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Product and Services
    • 2.3.4 Sino Therapeutics Tofacitinib Citrate Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Sino Therapeutics Recent Developments/Updates
  • 2.4 Qilu Pharmaceutical
    • 2.4.1 Qilu Pharmaceutical Details
    • 2.4.2 Qilu Pharmaceutical Major Business
    • 2.4.3 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product and Services
    • 2.4.4 Qilu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Qilu Pharmaceutical Recent Developments/Updates
  • 2.5 CSPC Ouyi Pharmaceutical
    • 2.5.1 CSPC Ouyi Pharmaceutical Details
    • 2.5.2 CSPC Ouyi Pharmaceutical Major Business
    • 2.5.3 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product and Services
    • 2.5.4 CSPC Ouyi Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 CSPC Ouyi Pharmaceutical Recent Developments/Updates
  • 2.6 Yichang Humanwell Pharmaceutical
    • 2.6.1 Yichang Humanwell Pharmaceutical Details
    • 2.6.2 Yichang Humanwell Pharmaceutical Major Business
    • 2.6.3 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product and Services
    • 2.6.4 Yichang Humanwell Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.6.5 Yichang Humanwell Pharmaceutical Recent Developments/Updates
  • 2.7 Sichuan Kelun Pharmaceutical
    • 2.7.1 Sichuan Kelun Pharmaceutical Details
    • 2.7.2 Sichuan Kelun Pharmaceutical Major Business
    • 2.7.3 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product and Services
    • 2.7.4 Sichuan Kelun Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.7.5 Sichuan Kelun Pharmaceutical Recent Developments/Updates
  • 2.8 Lepu Pharmaceutical
    • 2.8.1 Lepu Pharmaceutical Details
    • 2.8.2 Lepu Pharmaceutical Major Business
    • 2.8.3 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Product and Services
    • 2.8.4 Lepu Pharmaceutical Tofacitinib Citrate Extended-Release Tablets Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2021-2026)
    • 2.8.5 Lepu Pharmaceutical Recent Developments/Updates

3 Competitive Environment: Tofacitinib Citrate Extended-Release Tablets by Manufacturer

  • 3.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Manufacturer (2021-2026)
  • 3.2 Global Tofacitinib Citrate Extended-Release Tablets Revenue by Manufacturer (2021-2026)
  • 3.3 Global Tofacitinib Citrate Extended-Release Tablets Average Price by Manufacturer (2021-2026)
  • 3.4 Market Share Analysis (2025)
    • 3.4.1 Producer Shipments of Tofacitinib Citrate Extended-Release Tablets by Manufacturer Revenue ($MM) and Market Share (%): 2025
    • 3.4.2 Top 3 Tofacitinib Citrate Extended-Release Tablets Manufacturer Market Share in 2025
    • 3.4.3 Top 6 Tofacitinib Citrate Extended-Release Tablets Manufacturer Market Share in 2025
  • 3.5 Tofacitinib Citrate Extended-Release Tablets Market: Overall Company Footprint Analysis
    • 3.5.1 Tofacitinib Citrate Extended-Release Tablets Market: Region Footprint
    • 3.5.2 Tofacitinib Citrate Extended-Release Tablets Market: Company Product Type Footprint
    • 3.5.3 Tofacitinib Citrate Extended-Release Tablets Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Tofacitinib Citrate Extended-Release Tablets Market Size by Region
    • 4.1.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Region (2021-2032)
    • 4.1.2 Global Tofacitinib Citrate Extended-Release Tablets Consumption Value by Region (2021-2032)
    • 4.1.3 Global Tofacitinib Citrate Extended-Release Tablets Average Price by Region (2021-2032)
  • 4.2 North America Tofacitinib Citrate Extended-Release Tablets Consumption Value (2021-2032)
  • 4.3 Europe Tofacitinib Citrate Extended-Release Tablets Consumption Value (2021-2032)
  • 4.4 Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Consumption Value (2021-2032)
  • 4.5 South America Tofacitinib Citrate Extended-Release Tablets Consumption Value (2021-2032)
  • 4.6 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Consumption Value (2021-2032)

5 Market Segment by Type

  • 5.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Type (2021-2032)
  • 5.2 Global Tofacitinib Citrate Extended-Release Tablets Consumption Value by Type (2021-2032)
  • 5.3 Global Tofacitinib Citrate Extended-Release Tablets Average Price by Type (2021-2032)

6 Market Segment by Application

  • 6.1 Global Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Application (2021-2032)
  • 6.2 Global Tofacitinib Citrate Extended-Release Tablets Consumption Value by Application (2021-2032)
  • 6.3 Global Tofacitinib Citrate Extended-Release Tablets Average Price by Application (2021-2032)

7 North America

  • 7.1 North America Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Type (2021-2032)
  • 7.2 North America Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Application (2021-2032)
  • 7.3 North America Tofacitinib Citrate Extended-Release Tablets Market Size by Country
    • 7.3.1 North America Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Country (2021-2032)
    • 7.3.2 North America Tofacitinib Citrate Extended-Release Tablets Consumption Value by Country (2021-2032)
    • 7.3.3 United States Market Size and Forecast (2021-2032)
    • 7.3.4 Canada Market Size and Forecast (2021-2032)
    • 7.3.5 Mexico Market Size and Forecast (2021-2032)

8 Europe

  • 8.1 Europe Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Type (2021-2032)
  • 8.2 Europe Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Application (2021-2032)
  • 8.3 Europe Tofacitinib Citrate Extended-Release Tablets Market Size by Country
    • 8.3.1 Europe Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Country (2021-2032)
    • 8.3.2 Europe Tofacitinib Citrate Extended-Release Tablets Consumption Value by Country (2021-2032)
    • 8.3.3 Germany Market Size and Forecast (2021-2032)
    • 8.3.4 France Market Size and Forecast (2021-2032)
    • 8.3.5 United Kingdom Market Size and Forecast (2021-2032)
    • 8.3.6 Russia Market Size and Forecast (2021-2032)
    • 8.3.7 Italy Market Size and Forecast (2021-2032)

9 Asia-Pacific

  • 9.1 Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Type (2021-2032)
  • 9.2 Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Application (2021-2032)
  • 9.3 Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Market Size by Region
    • 9.3.1 Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Region (2021-2032)
    • 9.3.2 Asia-Pacific Tofacitinib Citrate Extended-Release Tablets Consumption Value by Region (2021-2032)
    • 9.3.3 China Market Size and Forecast (2021-2032)
    • 9.3.4 Japan Market Size and Forecast (2021-2032)
    • 9.3.5 South Korea Market Size and Forecast (2021-2032)
    • 9.3.6 India Market Size and Forecast (2021-2032)
    • 9.3.7 Southeast Asia Market Size and Forecast (2021-2032)
    • 9.3.8 Australia Market Size and Forecast (2021-2032)

10 South America

  • 10.1 South America Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Type (2021-2032)
  • 10.2 South America Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Application (2021-2032)
  • 10.3 South America Tofacitinib Citrate Extended-Release Tablets Market Size by Country
    • 10.3.1 South America Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Country (2021-2032)
    • 10.3.2 South America Tofacitinib Citrate Extended-Release Tablets Consumption Value by Country (2021-2032)
    • 10.3.3 Brazil Market Size and Forecast (2021-2032)
    • 10.3.4 Argentina Market Size and Forecast (2021-2032)

11 Middle East & Africa

  • 11.1 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Type (2021-2032)
  • 11.2 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Application (2021-2032)
  • 11.3 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Market Size by Country
    • 11.3.1 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Sales Quantity by Country (2021-2032)
    • 11.3.2 Middle East & Africa Tofacitinib Citrate Extended-Release Tablets Consumption Value by Country (2021-2032)
    • 11.3.3 Turkey Market Size and Forecast (2021-2032)
    • 11.3.4 Egypt Market Size and Forecast (2021-2032)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2021-2032)
    • 11.3.6 South Africa Market Size and Forecast (2021-2032)

12 Market Dynamics

  • 12.1 Tofacitinib Citrate Extended-Release Tablets Market Drivers
  • 12.2 Tofacitinib Citrate Extended-Release Tablets Market Restraints
  • 12.3 Tofacitinib Citrate Extended-Release Tablets Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Tofacitinib Citrate Extended-Release Tablets and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Tofacitinib Citrate Extended-Release Tablets
  • 13.3 Tofacitinib Citrate Extended-Release Tablets Production Process
  • 13.4 Industry Value Chain Analysis

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Tofacitinib Citrate Extended-Release Tablets Typical Distributors
  • 14.3 Tofacitinib Citrate Extended-Release Tablets Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Tofacitinib Citrate Extended-Release Tablets. Industry analysis & Market Report on Tofacitinib Citrate Extended-Release Tablets is a syndicated market report, published as Global Tofacitinib Citrate Extended-Release Tablets Market 2026 by Manufacturers, Regions, Type and Application, Forecast to 2032. It is complete Research Study and Industry Analysis of Tofacitinib Citrate Extended-Release Tablets market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,690.04
    		4,035.06
    		5,380.08
    		3,239.88
    		4,859.82
    		6,479.76
    		531,361.20
    		797,041.80
    		1,062,722.40
    		293,712.00
    		440,568.00
    		587,424.00
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo